Reviewing Phathom Pharmaceuticals (NASDAQ:PHAT) and OS Therapies (NYSE:OSTX)

OS Therapies (NYSE:OSTX) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Valuation and Earnings

This table compares OS Therapies and Phathom Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OS Therapies	N/A	N/A	-$7.79 million	N/A	N/A
Phathom Pharmaceuticals	$55.25 million	8.32	-$201.59 million	($5.35)	-1.23

OS Therapies has higher earnings, but lower revenue than Phathom Pharmaceuticals.

Insider and Institutional Ownership

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 13.8% of OS Therapies shares are held by company insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for OS Therapies and Phathom Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OS Therapies	0	0	2	2	3.50
Phathom Pharmaceuticals	0	1	4	1	3.00

OS Therapies currently has a consensus target price of $17.50, suggesting a potential upside of 980.25%. Phathom Pharmaceuticals has a consensus target price of $22.17, suggesting a potential upside of 235.86%. Given OS Therapies’ stronger consensus rating and higher possible upside, analysts plainly believe OS Therapies is more favorable than Phathom Pharmaceuticals.

Profitability

This table compares OS Therapies and Phathom Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OS Therapies	N/A	N/A	-569.57%
Phathom Pharmaceuticals	-1,292.14%	N/A	-79.57%

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.